Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDX-0158 |
Synonyms | |
Therapy Description |
CDX-0158 (KTN0158) is a humanized anti-cKIT antibody that inhibits KIT signaling, resulting in inhibition of cell proliferation (Mol Cancer Ther December 2015 14; C167, PMID: 28138031). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-0158 | KTN0158|CDX 0158|KTN 0158 | KIT Inhibitor 57 | CDX-0158 (KTN0158) is a humanized anti-cKIT antibody that inhibits KIT signaling, resulting in inhibition of cell proliferation (Mol Cancer Ther December 2015 14; C167, PMID: 28138031). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02642016 | Phase I | CDX-0158 | A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |